Arvinas, Inc. (ARVN)Healthcare | Biotechnology | New Haven, United States | NasdaqGS
6.82 USD
-0.02
(-0.292%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 6.82 |
Hot Take ↕ | Oct. 10, 2026, 4:13 a.m. EDT
The immediate catalyst driving this trade is the FDA approval of the breast cancer drug, which sent shares jumping 10% and lifted analyst forecasts. This regulatory win validates the company's pipeline and provides the necessary momentum to break out of its downtrend. However, the long-term picture remains precarious due to a severe multi-year structural decline; the stock has lost nearly 35% of its value over the last seven years, with the most recent annual return being a crushing -62%. While the business shows signs of life with positive operating margins and a fortress-like balance sheet relative to its tiny debt load, the market has punished the asset heavily for past execution failures. The statistical forecast model offers no directional bias, reflecting the uncertainty surrounding whether this latest approval can reverse a decade-long slide. Consequently, the short-term outlook is neutral-to-slightly-bullish as traders digest the news, but the long-term investment case remains neutral until the company can demonstrate sustained revenue growth and a reversal of the multi-year price trajectory. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.075640 |
| MSTL | 0.081977 |
| AutoETS | 0.088860 |
| AutoTheta | 0.091840 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 0.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.320 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.423 |
| Revenue per Share | 4.748 |
| Market Cap | 445,933,856 |
| Trailing P/E | 26.23 |
| Forward P/E | -2.11 |
| Beta | 1.81 |
| Profit Margins | 2.94% |
| Website | https://www.arvinas.com |
As of Oct. 10, 2026, 4:13 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. Call volume is heavily skewed toward out-of-the-money strikes (14.0 and 27.0 for Jan 2027), suggesting a hope for a massive rally to $15+, while put volume concentrates at lower strikes (5.0 and 6.0 for Jan 2027), indicating a fear of a drop to $5. The lack of in-the-money positioning on both sides suggests the market views the current price as a pivot point with binary outcomes ahead, rather than a steady trend.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2769556 |
| Address1 | 5 Science Park |
| Address2 | 395 Winchester Avenue |
| All Time High | 108.47 |
| All Time Low | 5.9 |
| Ask | 8.81 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 2.4 - Buy |
| Average Daily Volume10 Day | 719,720 |
| Average Daily Volume3 Month | 790,979 |
| Average Volume | 790,979 |
| Average Volume10Days | 719,720 |
| Beta | 1.809 |
| Bid | 5.26 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 8.609 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.82 |
| Current Ratio | 7.905 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.96 |
| Day Low | 6.74 |
| Debt To Equity | 1.423 |
| Display Name | Arvinas |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,844,800 |
| Earnings Call Timestamp Start | 1,785,844,800 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -9,900,000 |
| Ebitda Margins | -0.03126 |
| Enterprise To Ebitda | 11.38 |
| Enterprise To Revenue | -0.356 |
| Enterprise Value | -112,658,456 |
| Eps Current Year | -0.13698 |
| Eps Forward | -3.23187 |
| Eps Trailing Twelve Months | 0.26 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.5068 |
| Fifty Day Average Change | -1.6867995 |
| Fifty Day Average Change Percent | -0.19828838 |
| Fifty Two Week Change Percent | -27.69556 |
| Fifty Two Week High | 14.51 |
| Fifty Two Week High Change | -7.69 |
| Fifty Two Week High Change Percent | -0.52997935 |
| Fifty Two Week Low | 6.74 |
| Fifty Two Week Low Change | 0.0800004 |
| Fifty Two Week Low Change Percent | 0.011869496 |
| Fifty Two Week Range | 6.74 - 14.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,055,000,000 |
| Float Shares | 56,812,754 |
| Forward Eps | -3.23187 |
| Forward P E | -2.1102335 |
| Free Cashflow | -94,500,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 246 |
| Fullday Change | -0.01999998 |
| Fullday Change Percent | -0.29239738 |
| Fullday Price | 6.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.97157997 |
| Gross Profits | 307,700,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07802 |
| Held Percent Institutions | 0.83973 |
| Implied Shares Outstanding | 65,386,191 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. |
| Long Name | Arvinas, Inc. |
| Market | us_market |
| Market Cap | 445,933,856 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_243040896 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 9,300,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 511,320,013 |
| Number Of Analyst Opinions | 14 |
| Open | 6.77 |
| Operating Cashflow | -207,000,000 |
| Operating Margins | 0.6636 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 203 535 1456 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.82 |
| Post Market Time | 1,792,008,078 |
| Previous Close | 6.84 |
| Price Eps Current Year | -49.788292 |
| Price Hint | 2 |
| Price To Book | 0.7921942 |
| Price To Sales Trailing12 Months | 1.408064 |
| Profit Margins | 0.02937 |
| Quick Ratio | 7.542 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.375 |
| Region | US |
| Regular Market Change | -0.01999998 |
| Regular Market Change Percent | -0.29239738 |
| Regular Market Day High | 6.96 |
| Regular Market Day Low | 6.74 |
| Regular Market Day Range | 6.74 - 6.96 |
| Regular Market Open | 6.77 |
| Regular Market Previous Close | 6.84 |
| Regular Market Price | 6.82 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 856,959 |
| Return On Assets | -0.0101 |
| Return On Equity | 0.01588 |
| Revenue Growth | 10.147 |
| Revenue Per Share | 4.748 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 65,386,191 |
| Shares Percent Shares Out | 0.082399994 |
| Shares Short | 5,389,277 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,711,553 |
| Short Name | Arvinas, Inc. |
| Short Percent Of Float | 0.096099995 |
| Short Ratio | 6.31 |
| Source Interval | 15 |
| State | CT |
| Symbol | ARVN |
| Target High Price | 21.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 13.92857 |
| Target Median Price | 13.0 |
| Total Cash | 567,900,032 |
| Total Cash Per Share | 8.685 |
| Total Debt | 8,000,000 |
| Total Revenue | 316,700,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.26 |
| Trailing P E | 26.23077 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.9803 |
| Two Hundred Day Average Change | -3.1602998 |
| Two Hundred Day Average Change Percent | -0.3166538 |
| Type Disp | Equity |
| Volume | 856,959 |
| Website | https://www.arvinas.com |
| Zip | 6,511 |